SLC5A2 and fatty liver disease: Figure 2 demonstrates the change in the percentages of liver steatosis in diabetic patients measured by MRI_PDFF in the right lobe, left lobe, and area around IVC in the posterior aspect of the right lobe at baseline and after treatment with SGLT2 inhibitor Empagliflozin 10 mg for 24 weeks.